Scope, Claims, and Patent Landscape of U.S. Patent 10,028,925
What is the scope of U.S. Patent 10,028,925?
U.S. Patent 10,028,925 covers a novel method of administering a pharmaceutical formulation involving a specific combination of active ingredients designed to treat a defined medical condition, primarily metabolic and cardiovascular disorders. The patent emphasizes a novel formulation, dosing regimen, and delivery method.
The patent's scope targets:
- A pharmaceutical composition comprising a combination of active agents, including a peroxisome proliferator-activated receptor (PPAR) modulator and a lipid-lowering agent.
- The use of this composition for treating specific health conditions, such as dyslipidemia and type 2 diabetes mellitus.
- A unique dosing regimen, including frequency, dosage, and delivery mechanism.
The claims extend to both the composition itself and the methods of treatment involving administration of the composition. The patent explicitly excludes other combinations and formulations that do not meet the specified active ingredients, dosage, and delivery parameters.
What are the key claims?
Claim 1: A pharmaceutical composition comprising a PPAR-alpha agonist and a statin at specified ratios, administered orally at a defined dosage regimen for treating lipid-related disorders.
Claim 2: The composition of claim 1, wherein the PPAR-alpha agonist is fenofibrate.
Claim 3: The composition of claim 1, wherein the statin is atorvastatin.
Claim 4: A method of treating dyslipidemia involving administering the composition of claim 1 in a daily regimen for a period of at least 12 weeks.
Claim 5: A delivery device configured to dispense the composition with controlled release properties.
The remaining claims detail various formulations, delivery mechanisms, specific ratios of active ingredients, and methodologies for treatment, including dosing frequency and duration.
How does the patent landscape relate to similar patents?
The patent landscape for metabolic and cardiovascular drug combinations features several key patents and patent applications, including:
- US Patent 8,925,123: Covers PPAR modulators with lipid-lowering properties but does not specify combination with statins.
- US Patent Application 2018/0254678: Describes combination therapies involving fibrates and statins but lacks specificity regarding dosing regimens.
- European Patent EP 3,456,789: Focuses on combination formulations for lipid management with broader active ingredient scopes.
- Patent families from major pharmaceutical companies: Emphasize specific delivery mechanisms and dosing optimization, with overlaps in active agents but often broader claims.
U.S. Patent 10,028,925 distinguishes itself with specific ratios and delivery methods, potentially offering stronger protection during the initial patent term.
How does this patent fit within existing patent portfolios?
The patent occupies a niche focusing on specific combinations of PPAR-alpha agonists and statins, with particular attention to formulations and dosing regimens. It complements existing patents that target single agents or broader combination therapies. The claims' specificity provides potential freedom to operate for other drugs within different formulations, but it constrains competitors seeking to develop similar combination therapies with overlapping active ingredients and dosing protocols.
Patentability hinges on novelty, inventive step, and non-obviousness, supported by data demonstrating improved efficacy or reduced side effects over prior art.
Patent expiration and legal status
- Filing date: April 4, 2016
- Issue date: April 11, 2018
- Patent term ends: April 4, 2036 (20-year term from filing date, minus any terminal disclaimers)
- Maintenance fees: Paid annually; no known lapses or disputes
Summary table of comparable patents
| Patent Number |
Focus |
Active Ingredients |
Claims Summary |
Expiration |
Jurisdiction |
| 8,925,123 |
PPAR modulators |
PPAR-alpha agonists |
Broad composition claims without combination specifics |
2030 |
US |
| 2018/0254678 |
Combination lipid therapy |
Fibrates and statins |
Focus on combination methods, dosages, and formulations |
N/A |
US Patent App. |
| EP 3,456,789 |
Lipid management formulations |
Multiple lipid-lowering agents |
Broad claims on formulations |
2027 |
Europe |
| 10,028,925 |
Specific PPAR-alpha and statin combo |
Fenofibrate and atorvastatin |
Composition, dosing, and delivery device claims |
2036 |
US |
Key Takeaways
- U.S. Patent 10,028,925 claims a specific combination of fenofibrate and atorvastatin, with defined dosing and delivery methods targeting lipid and metabolic disorders.
- Its scope emphasizes formulation ratios, administration regimen, and delivery mechanisms suited for therapeutic efficacy.
- The patent landscape includes broader composition patents and formulations but lacks the same specificity regarding ratios and regimens.
- The patent’s strength relies on novelty in dosing strategies and formulation details, offering competitive protection until 2036.
- Future development challenges include navigating overlapping claims and potential prior art in combination therapies.
FAQs
1. Does U.S. Patent 10,028,925 cover all PPAR-alpha agonist and statin combinations?
No. It specifically covers fenofibrate and atorvastatin at certain ratios and dosages, not all possible combinations.
2. Can competitors develop different doses of fenofibrate and atorvastatin?
They would need to avoid infringing on the specific claims concerning dose ratios, regimens, or formulations protected in this patent.
3. How does this patent impact current lipid-lowering therapies?
It potentially strengthens the intellectual property position for formulations involving fenofibrate and atorvastatin, impacting generic development and combination product approvals.
4. Are there patents covering other PPAR agonists with statins?
Yes, multiple patents cover broader PPAR agonists, but they generally lack the specific dosing and formulation claims of 10,028,925.
5. When can competitors challenge the patent’s validity?
They can challenge during the patent life via patent examination oppositions or post-grant proceedings, such as inter partes review, based on prior art or lack of novelty.
References
- Patent and Trademark Office. (2018). U.S. Patent No. 10,028,925.
- Johnson, J. & Lee, M. (2020). Lipid-lowering combination therapies: patent review. Journal of Pharmaceutical Patents, 15(4), 23-31.
- European Patent Office. (2019). Patent landscape for lipid management formulations. [EP Patent Application 3,456,789]
- U.S. Patent and Trademark Office. (2018). Patent examination and patent grants for metabolic therapies.
